Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It?Zacks Investment Research • 09/17/26
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 09/15/26
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research • 09/15/26
CRISPR Therapeutics AG (CRSP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/14/26
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/11/26
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/11/26
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire • 09/08/26
CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition CaseSeeking Alpha • 09/05/26
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026The Motley Fool • 09/02/26
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?Zacks Investment Research • 09/02/26
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026GlobeNewsWire • 08/28/26
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?The Motley Fool • 08/21/26
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/26
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial ResultsGlobeNewsWire • 08/03/26
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to ConsiderZacks Investment Research • 07/30/26